Early phase oncology expertise and established local relationships make George Clinical the CRO of choice for Chinese biotech.
Our organization’s nimble, flexible approach to early phase oncology trials was a large benefit to an innovative, global Chinese biotech for a phase I, multicenter, open-label, dose-escalation, oncology clinical trial in Australia. Australia was chosen due to its streamlined Clinical Trial Notification (CTN) system, the capabilities of Australian sites in undertaking early phase oncology trials and the country’s R&D Tax Incentive.
Timeliness of trial conduct was critical to the sponsor’s development plans. Solid relationships with practicing oncologists were necessary to support site selection and recruitment goals. Patient safety and consideration required a study design that reduced the patient burden.
Download the complete case study by filling out the form.